| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the National Jewish Medical and Research Center (Dr. Nelson), Denver, CO; Brigham and Women’s Hospital and Harvard Medical School (Dr. Weiss), Boston, MA; Wake Forest University School of Medicine (Dr. Bleecker), Winston Salem, NC; and GlaxoSmithKline (Mr. Yancey and Dr. Dorinsky), Research Triangle Park, NC.
Correspondence to: Paul M. Dorinsky, MD, GlaxoSmithKline, 5 Moore Dr, Research Triangle Park, NC 27709; e-mail: paul.m.dorinsky{at}gsk.com
Abstract
Study objective: To compare the safety of salmeterol xinafoate or placebo added to usual asthma care.
Design: A 28-week, randomized, double-blind, placebo-controlled, observational study.
Setting: Study subjects were seen once in the study physician’s office for screening and were provided all blinded study medication for the entire study period. Follow-up by telephone was scheduled every 4 weeks.
Participants: Subjects (> 12 years old) with asthma as judged by the study physician were eligible. Individuals with a history of long-acting ß2-agonist use were excluded.
Interventions: Salmeterol, 42 µg bid via metered-dose inhaler (MDI), and placebo bid via MDI.
Measurements and results: Following an interim analysis in 26,355 subjects, the study was terminated due to findings in African Americans and difficulties in enrollment. The occurrence of the primary outcome, respiratory-related deaths, or life-threatening experiences was low and not significantly different for salmeterol vs placebo (50 vs 36; relative risk [RR] = 1.40; 95% confidence interval [CI], 0.91 to 2.14). There was a small, significant increase in respiratory-related deaths (24 vs 11; RR, 2.16; 95% CI, 1.06 to 4.41) and asthma-related deaths (13 vs 3; RR, 4.37; 95% CI, 1.25 to 15.34), and in combined asthma-related deaths or life-threatening experiences (37 vs 22; RR, 1.71; 95% CI, 1.01 to 2.89) in subjects receiving salmeterol vs placebo. The imbalance occurred largely in the African-American subpopulation: respiratory-related deaths or life-threatening experiences (20 vs 5; RR, 4.10; 95% CI, 1.54 to 10.90) and combined asthma-related deaths or life-threatening experiences (19 vs 4; RR, 4.92; 95% CI, 1.68 to 14.45) in subjects receiving salmeterol vs placebo.
Conclusions: For the primary end point in the total population, there were no significant differences between treatments. There were small, but statistically significant increases in respiratory-related and asthma-related deaths and combined asthma-related deaths or life-threatening experiences in the total population receiving salmeterol. Subgroup analyses suggest the risk may be greater in African Americans compared with Caucasian subjects. Whether this risk is due to factors including but not limited to a physiologic treatment effect, genetic factors, or patient behaviors leading to poor outcomes remains unknown.
Key Words: asthma • long-acting ß2-agonist • salmeterol
This article has been cited by other articles:
|
|
 |
|
  E. Bateman, H. Nelson, J. Bousquet, K. Kral, L. Sutton, H. Ortega, and S. Yancey Meta-analysis: Effects of Adding Salmeterol to Inhaled Corticosteroids on Serious Asthma-Related Events Ann Intern Med, June 3, 2008; (2008) 0000605-200807010-00229. [Abstract] [Full Text]
|
|
|
|
|
|
K. B. Weiss Drug Safety and Salmeterol: The Controversy Continues Ann Intern Med, June 3, 2008; (2008) 0000605-200807010-00230. [Full Text]
|
|
|
|
 |
|
 M. R. Sears Long-Acting Bronchodilators in COPD Chest, May 1, 2008; 133(5): 1057 - 1058. [Full Text] [PDF]
|
|
|
|
|
|
N. A. Hanania Targeting Airway Inflammation in Asthma: Current and Future Therapies Chest, April 1, 2008; 133(4): 989 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ernst, A. McIvor, F. M. Ducharme, L.-P. Boulet, M. FitzGerald, K. R. Chapman, T. Bai, and for the Canadian Asthma Guideline Group Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med, November 7, 2006; 145(9): 692 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Salpeter Safety of Long-Acting {beta}-Agonists. Ann Intern Med, November 7, 2006; 145(9): 708 - 710. [Full Text] [PDF]
|
|
|
|
 |
|
 S B Liggett Genetic variability of the {beta}2 adrenergic receptor and asthma exacerbations. Thorax, November 1, 2006; 61(11): 925 - 927. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Adelsberg Combined budesonide and formoterol for maintenance and relief provided better asthma control than budesonide for maintenance and terbutaline for relief Evid. Based Med., October 1, 2006; 11(5): 138 - 138. [Full Text] [PDF]
|
|
|
|
|
|
R. J Lipchik Addition of salmeterol to usual asthma pharmacotherapy may increase respiratory related deaths or life threatening experiences Evid. Based Med., October 1, 2006; 11(5): 139 - 139. [Full Text] [PDF]
|
|
|
|
|
|
M. R. Sears, H. S. Nelson, and P. M. Dorinsky The salmeterol multicenter asthma research trial. Chest, September 1, 2006; 130(3): 928 - 929. [Full Text] [PDF]
|
|
|
|
|
|
G. P. Currie, H. S. Nelson, and P. M. Dorinsky Why SMART About Second-Line Treatment When First-Line Treatment Is Being Ignored? Chest, September 1, 2006; 130(3): 929 - 929. [Full Text] [PDF]
|
|
|
|
|
|
S. M. Seymour, E. J. Sullivan, B. A. Chowdhury, R. J. Meyer, R. C. Davi, H. S. Nelson, and P. M. Dorinsky Comments on the salmeterol multicenter asthma research trial. Chest, September 1, 2006; 130(3): 930 - 931. [Full Text] [PDF]
|
|
|
|
 |
|
 T. K. Trow Clinical Year in Review I: Diagnostic Imaging, Asthma, Lung Transplantation, and Interventional Pulmonology Proceedings of the ATS, September 1, 2006; 3(7): 553 - 556. [Full Text] [PDF]
|
|
|
|
|
|
C. Williams, H. S. Nelson, and P. M. Dorinsky Cause of Death in the SMART Trial. Chest, September 1, 2006; 130(3): 929 - 930. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Weinberger and M. Abu-Hasan Life-Threatening Asthma during Treatment with Salmeterol N. Engl. J. Med., August 24, 2006; 355(8): 852 - 853. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bell and R. A. McIvor SMART therapy. Can. Med. Assoc. J., August 1, 2006; 175(3): 276 - 277. [Full Text] [PDF]
|
|
|
|
|
|
J. Glassroth The Role of Long-Acting {beta}-Agonists in the Management of Asthma: Analysis, Meta-Analysis, and More Analysis Ann Intern Med, June 20, 2006; 144(12): 936 - 937. [Full Text] [PDF]
|
|
|
|
|
|
S. R. Salpeter, N. S. Buckley, T. M. Ormiston, and E. E. Salpeter Meta-Analysis: Effect of Long-Acting {beta}-Agonists on Severe Asthma Exacerbations and Asthma-Related Deaths Ann Intern Med, June 20, 2006; 144(12): 904 - 912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Williams Considerations in the long-term management of asthma in ambulatory patients Am. J. Health Syst. Pharm., May 15, 2006; 63(10_Supplement_3): S14 - S21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rees Asthma control in adults. BMJ, April 1, 2006; 332(7544): 767 - 771. [Full Text] [PDF]
|
|
|
|
 |
|
 Salmeterol and Asthma-Related Deaths Journal Watch (General), February 17, 2006; 2006(217): 4 - 4. [Full Text]
|
|
|
|
|
|
P. M. O'Byrne and E. Adelroth {beta}2 Deja Vu Chest, January 1, 2006; 129(1): 3 - 5. [Full Text] [PDF]
|
|
|
|
|
|
J. Wolfe, C. LaForce, B. Friedman, W. Sokol, D. Till, G. Della Cioppa, and A. van As Formoterol, 24 {micro}g bid, and Serious Asthma Exacerbations: Similar Rates Compared With Formoterol, 12 {micro}g bid, With and Without Extra Doses Taken on Demand, and Placebo Chest, January 1, 2006; 129(1): 27 - 38. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
